Add BrightSurf on Google Email

Alliance reports results from first randomized trial of a radiopharmaceutical in kidney cancer

The RadiCaL study, the first randomized trial of a radiopharmaceutical in kidney cancer, found that adding radium-223 to the standard of care does not improve skeletal event-free survival. Patients who received the combination treatment lived a median of 28.3 months, compared with 19.7 months for those who received cabozantinib alone.

SourceAlliance for Clinical Trials in Oncology·JournalJournal of Clinical Oncology·TypeExperimental study·DateAug 17, 2026

Aston University research sheds more light on the antimicrobial properties of mānuka honey

New research at Aston University shows that mānuka honey's effectiveness against disease-causing bacteria cannot be attributed solely to its sugar content and methylglyoxal levels. The study identified additional bioactive compounds responsible for the antimicrobial activity, which may lead to the development of more effective honey-de...

SourceAston University·JournalMicrobiology·TypeExperimental study·DateAug 11, 2026

New antimicrobials could help tackle deadly drug-resistant infections

Researchers at the University of Manchester have developed a new family of antifungal agents that are more potent and less toxic than existing treatments. The compounds, which were discovered through genome mining, showed increased antifungal activity and improved solubility compared to existing drugs.

SourceUniversity of Manchester·JournalNature·DateJul 29, 2026
Meta Quest 3 512GB

Meta Quest 3 512GB enables immersive mission planning, terrain rehearsal, and interactive STEM demos with high-resolution mixed-reality experiences.

First patient enrolled in GOG-3132/BEHOLD-Ovarian01 phase 3 study evaluating Mocertatug Rezetecan, a novel B7-H4–targeted ADC, in platinum-resistant ovarian cancer

The first patient has been enrolled in a global Phase 3 clinical trial evaluating Mocertatug Rezetecan, a novel B7-H4-targeted ADC, in platinum-resistant ovarian cancer. The study aims to determine whether this therapy can improve outcomes compared with standard chemotherapy.

SourceThe GOG Foundation Inc·TypeRandomized controlled/clinical trial·DateJul 27, 2026

Children with severe pneumonia can leave hospital sooner after switching to oral antibiotics, landmark trial shows

A landmark trial shows that children hospitalised with severe pneumonia can recover just as well from injectable to oral antibiotics, even with shorter treatment durations. This simple change could help millions of children worldwide get back to their families sooner and reduce pressure on busy hospitals.

SourceCity St George’s, University of London·JournalThe Lancet·TypeRandomized controlled/clinical trial·DateJul 23, 2026

GLP-1 shows promise for patients with advanced fatty liver disease

A clinical trial showed semaglutide improved liver scarring in patients with advanced fatty liver disease and early-stage cirrhosis. Non-invasive blood tests reflected treatment-related improvements more clearly than liver biopsies, which could reduce reliance on invasive procedures.

SourceUniversity of California - San Diego·JournalThe Lancet Gastroenterology & Hepatology·DateJul 16, 2026
AmScope B120C-5M Compound Microscope

AmScope B120C-5M Compound Microscope supports teaching labs and QA checks with LED illumination, mechanical stage, and included 5MP camera.

Bile acid buildup drives spread of breast cancer, discovery reveals

A buildup of bile acids caused by an unhealthy gut can drive breast cancer to other parts of the body, researchers reveal. The study found that replenishing beneficial bacteria or treating patients with FDA-approved bile acid sequestrants may reduce breast cancer metastasis.

SourceUniversity of Virginia Health System·JournalCancer Research·DateJul 15, 2026

Researchers suggest ways to improve US sentencing guidelines

Researchers suggest separate weight-driven tables for different types of defendants, eliminating disparities in crack and methamphetamine sentences. The study proposes alternative approaches to define relative sentences for psychostimulants and opioids based on harms associated with each type of drug.

SourceCarnegie Mellon University·JournalFederal Sentencing Reporter·DateJul 14, 2026

OYE Therapeutics reports successful Phase 1 results for OYE-101 proprietary intravenous caffeine solution

OYE Therapeutics announced positive Phase 1 results for OYE-101, a proprietary intravenous caffeine formulation. The study demonstrated the safety and tolerability of OYE-101 in healthy adult volunteers, supporting its planned development as a treatment to support emergence from general anesthesia and deep sedation.

SourcePurdue University·TypeRandomized controlled/clinical trial·DateJul 14, 2026
SAMSUNG T9 Portable SSD 2TB

SAMSUNG T9 Portable SSD 2TB transfers large imagery and model outputs quickly between field laptops, lab workstations, and secure archives.

Drug candidate treats severe fatty liver disease by protecting the gut in animal models

Researchers discovered a potential drug developed at Michigan Medicine reverses metabolic dysfunction-associated steatohepatitis (MASH) in animal models by disrupting the disease-driving pathway that links the gut and liver. DT-109 improved gut health, reducing inflammation in livers of nonhuman primates.

SourceMichigan Medicine - University of Michigan·JournalJournal of Clinical Investigation·TypeExperimental study·DateJul 7, 2026

The University of Colorado Anschutz, along with UCHealth and Children’s Hospital Colorado, form strategic alliance with Bayer to advance drug development and clinical trials

The University of Colorado Anschutz, along with UCHealth and Children’s Hospital Colorado, have formed a strategic alliance with Bayer to accelerate medical discovery and expand patient access to investigational therapies. Initial focus areas include oncology, cardiovascular disease, and cell and gene therapy.

SourceUniversity of Colorado Anschutz·DateJul 7, 2026
Apple iPhone 17 Pro

Apple iPhone 17 Pro delivers top performance and advanced cameras for field documentation, data collection, and secure research communications.

New drug for chronic heart failure tested in early study

A new oral drug AC01 has been shown to improve heart function and be well-tolerated in patients with chronic heart failure. The study found no serious side effects and suggested potential clinical benefits, warranting further investigation.

SourceKarolinska Institutet·JournalThe Lancet·TypeRandomized controlled/clinical trial·DateJun 24, 2026
Aranet4 Home CO2 Monitor

Aranet4 Home CO2 Monitor tracks ventilation quality in labs, classrooms, and conference rooms with long battery life and clear e-ink readouts.

A nasal spray reaches a woman's brain differently depending on the week, and it may explain why a promising brain drug looked like a failure

A new study found that intranasal davunetide reaches the brain in higher amounts in female mice when estrogen peaks, with similar results seen in healthy adults. The findings suggest earlier trials mixing males and females may have obscured the true effects of the drug.

SourceGenomic Press·JournalGenomic Psychiatry·TypeExperimental study·DateJun 16, 2026

UVA joins SPARK GLOBAL to accelerate innovative new medicines

The University of Virginia has joined SPARK GLOBAL to leverage resources and expertise in accelerating the development of new medicines. This collaboration aims to reduce time from lab discoveries to clinic trials, delivering tangible healthcare solutions to patients.

SourceUniversity of Virginia Health System·DateJun 15, 2026
GoPro HERO13 Black

GoPro HERO13 Black records stabilized 5.3K video for instrument deployments, field notes, and outreach, even in harsh weather and underwater conditions.

Robert A. Winn Clinical Investigator Pathway Program announces cohort 5 awardees

Eighty medical students from across the US and Puerto Rico are selected for a six-week summer experience to introduce them to clinical research early in their careers. The program aims to develop the next generation of clinical investigators equipped to engage communities and improve participation in clinical trials.

SourceThe Robert A. Winn Excellence in Clinical Trials Award Program (Winn Awards)·DateJun 11, 2026
Apple iPad Pro 11-inch (M4)

Apple iPad Pro 11-inch (M4) runs demanding GIS, imaging, and annotation workflows on the go for surveys, briefings, and lab notebooks.

Ozempic, GPL-1s may help curb substance use disorders, UTEP study finds

A new UTEP study found that patients taking weight loss medications like Ozempic and GLP-1s have a lower risk of developing alcohol, opioid, nicotine, and cocaine use disorders. The study's findings suggest these medications may influence dopamine signaling and other neural pathways involved in cravings.

SourceUniversity of Texas at El Paso·JournalFrontiers in Psychiatry·DateJun 8, 2026

U-M hepatologist hails hepatitis B treatment trial results

Researchers have announced promising results of the B-Well clinical trials, showing that 20% and 19% of patients achieved a functional cure for their chronic hepatitis B infections after 24 weeks of bepirovirsen treatment. This represents a significant step towards developing a curative treatment for the disease.

SourceMichigan Medicine - University of Michigan·JournalNew England Journal of Medicine·TypeCommentary/editorial·DateMay 28, 2026

JMIR Report: Machine learning to fill research gaps in drug safety during pregnancy

Two projects, BOOST-HP and BIONIC, use machine learning to analyze large datasets of medication exposure and outcomes. The findings highlight the need for more data and cautious design of machine learning models to accurately assess potential links between medications and pregnant women.

SourceJMIR Publications·JournalJournal of Medical Internet Research·TypeCommentary/editorial·DateMay 27, 2026
Apple MacBook Pro 14-inch (M4 Pro)

Apple MacBook Pro 14-inch (M4 Pro) powers local ML workloads, large datasets, and multi-display analysis for field and lab teams.

Semaglutide effective for severe obesity even in young people who have been treatment resistant for many years, finds randomised controlled trial

A randomised controlled trial found semaglutide (Wegovy) significantly reduced BMI by 19% and fat mass in young adults with severe obesity, improving metabolic syndrome severity. The study suggests GLP-1 based treatment as a promising option for managing severe obesity in young people resistant to prior hospital-based care.

SourceEuropean Association for the Study of Obesity·DateMay 13, 2026

Study shows that most weight loss achieved using injectable obesity drugs can be maintained by switching to daily oral orforglipron (ATTAIN-MAINTAIN)

New research finds that participants in the ATTAIN-MAINTAIN trial maintained a significant percentage of weight loss when switched from injectable tirzepatide or semaglutide to daily oral orforglipron treatment. The study shows that nearly all weight loss achieved on injectable therapies can be maintained by switching to oral therapies.

SourceEuropean Association for the Study of Obesity·JournalNature Medicine·DateMay 12, 2026
Fluke 87V Industrial Digital Multimeter

Fluke 87V Industrial Digital Multimeter is a trusted meter for precise measurements during instrument integration, repairs, and field diagnostics.

People who have lost weight using tirzepatide are seven times more likely to maintain their weight loss if they continue on the maximum dose compared to those who stop treatment

Patients on tirzepatide at maximum dose have seven times higher odds of maintaining weight loss compared to those who stop treatment. Those on the lower 5mg dose have four times higher odds, according to a new study published in The Lancet.

SourceEuropean Association for the Study of Obesity·JournalThe Lancet·DateMay 12, 2026

New post-hoc analysis examined daily oral orforglipron in adults over 65 with obesity, with or without diabetes

A new post-hoc analysis examined daily oral orforglipron treatment for obesity, with or without diabetes, in users aged 65 years and over. The study found that orforglipron significantly reduced body weight and improved blood sugar markers compared to placebo, with a similar safety profile to the overall ATTAIN clinical trial population.

SourceEuropean Association for the Study of Obesity·DateMay 10, 2026
Rigol DP832 Triple-Output Bench Power Supply

Rigol DP832 Triple-Output Bench Power Supply powers sensors, microcontrollers, and test circuits with programmable rails and stable outputs.

ERASur colorectal cancer trial reaches one-third patient accrual milestone

The ERASur clinical trial is investigating whether total ablative therapy can improve overall survival in patients with newly diagnosed, limited metastatic colorectal cancer. The study has reached one-third patient accrual milestone, signaling strong momentum.

SourceAlliance for Clinical Trials in Oncology·TypeRandomized controlled/clinical trial·DateMay 6, 2026
Sky-Watcher EQ6-R Pro Equatorial Mount

Sky-Watcher EQ6-R Pro Equatorial Mount provides precise tracking capacity for deep-sky imaging rigs during long astrophotography sessions.

For women with primary progressive multiple sclerosis, could Roche’s best selling drug be doing more harm than good?

The FDA is reviewing a petition to revoke the approval of Roche's top-selling drug ocrelizumab for treating primary progressive multiple sclerosis in women due to concerns over its lack of effectiveness and potential increased risk of breast cancer. The investigation highlights internal FDA warnings about the drug's safety and effectiv...

SourceBMJ Group·JournalThe BMJ·DateApr 15, 2026

New drug doubles one-year survival in pancreatic cancer trial

A phase 2 clinical trial shows that a new drug, elraglusib, when combined with chemotherapy, doubles one-year survival rates in pancreatic cancer patients, reducing the risk of death by 38%. The study is a rare success in showing a survival benefit applicable to a broad population.

SourceNorthwestern University·JournalNature Medicine·DateApr 14, 2026

New AI technology to speed drug development

Scientists at the University of Virginia Health System have developed a suite of AI-powered tools, called YuelDesign, YuelPocket and YuelBond, to transform how new drugs are created. These tools can design drug molecules tailored to fit their protein targets exactly, even accounting for protein flexibility.

SourceUniversity of Virginia Health System·DateApr 9, 2026
GQ GMC-500Plus Geiger Counter

GQ GMC-500Plus Geiger Counter logs beta, gamma, and X-ray levels for environmental monitoring, training labs, and safety demonstrations.

Antidepressant unable to prevent chemotherapy-associated nerve damage

A randomized trial found that duloxetine does not prevent painful neuropathy caused by oxaliplatin-based chemotherapy in patients with stage II or III colorectal cancer. The study suggests that duloxetine should only be used for managing existing neuropathy, not prevention.

SourceAlliance for Clinical Trials in Oncology·JournalJCO Oncology Advances·TypeRandomized controlled/clinical trial·DateApr 8, 2026

Alliance marks Adolescent and Young Adult Cancer Awareness Week

The Alliance for Clinical Trials in Oncology is enrolling adolescent and young adult cancer patients in various trials, including genetic services and treatment studies. These trials aim to address longstanding gaps in care and improve outcomes for AYAs with cancer.

SourceAlliance for Clinical Trials in Oncology·DateApr 6, 2026
Nikon Monarch 5 8x42 Binoculars

Nikon Monarch 5 8x42 Binoculars deliver bright, sharp views for wildlife surveys, eclipse chases, and quick star-field scans at dark sites.

AstraZeneca joins Robert A. Winn Excellence in Clinical Trials Award Program as Funding Partner

The Robert A. Winn Excellence in Clinical Trials Award Program has partnered with AstraZeneca to support five medical students participating in the Winn Clinical Investigator Pathway Program (Winn CIPP). The program provides immersive training, mentorship, and hands-on experience to prepare students for careers in clinical research.

SourceThe Robert A. Winn Excellence in Clinical Trials Award Program (Winn Awards)·TypeNews article·DateMar 31, 2026

PSMA therapy delays hormone therapy in prostate cancer

A new study shows that PSMA therapy can delay the need for hormone therapy in prostate cancer patients by an average of 20 months. The therapy is effective in earlier stages of the disease, improving survival and quality of life for approximately two out of three patients.

SourceRadboud University Medical Center·JournalThe Lancet Oncology·TypeRandomized controlled/clinical trial·DateMar 30, 2026

Global trial supported by SickKids stem cell research shows targeted heart drug reduces obstructive HCM in youth

A global clinical trial led by SickKids has found that mavacamten improves blood flow and reduces obstruction in youth with hypertrophic cardiomyopathy (HCM), a genetic heart disease. The study's results offer hope to families avoiding open-heart surgery, setting the stage for precision therapeutics.

SourceThe Hospital for Sick Children·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateMar 29, 2026

Landmark Alliance ATOMIC Trial establishes new standard of care for patients with stage III dMMR colon cancer

The phase III Alliance ATOMIC trial shows that adding immunotherapy to standard chemotherapy improves clinical outcomes for patients with stage III dMMR colon cancer. The study found a 50% reduction in cancer recurrence risk and a 86.3% disease-free survival rate at three years.

SourceAlliance for Clinical Trials in Oncology·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateMar 25, 2026

Using new anti-obesity drugs in prevention of obesity-related cancers – global panel of experts suggest 10-year trial with 5,000 participants with cancer pre-cursor condition to establish efficacy

A global panel of experts recommends a 10-year trial with 5,000 participants at high risk of cancer due to pre-cursor conditions. The trial will evaluate the potential efficacy of GLP-1 and dual receptor agonists in preventing obesity-related cancers.

SourceEuropean Association for the Study of Obesity·DateMar 25, 2026
Sony Alpha a7 IV (Body Only)

Sony Alpha a7 IV (Body Only) delivers reliable low-light performance and rugged build for astrophotography, lab documentation, and field expeditions.

Answering an urgent need

The Linda and Mike Mussallem Foundation has donated to USC's Keck School of Medicine to enhance clinical trials for individuals with Down syndrome at risk for Alzheimer's. This will increase domestic and international sites, accelerating the development of treatments specifically for this population.

SourceKeck School of Medicine of USC·DateMar 25, 2026

New test dissolves threat of fake drugs

Researchers have developed a low-cost fake drug detector that uses an infrared sensor to track pill dissolution rates. The device can identify legitimate medications from counterfeit ones with high accuracy, making it a valuable tool in the fight against global health threats.

SourceUniversity of California - Riverside·JournalAnalytical Chemistry·DateMar 19, 2026

New alliance clinical trial aims to improve outcomes in brain tumors

A new clinical trial will investigate whether adding the oral medication vorasidenib to standard chemotherapy improves progression-free survival for people with newly-diagnosed, grade 3 IDH-mutant astrocytoma. The study aims to recruit 400 individuals with this type of brain cancer and evaluate the safety and side-effect profile of the...

SourceAlliance for Clinical Trials in Oncology·DateMar 16, 2026

NRG Oncology/Alliance trial finds immunotherapy did not improve survival when added to chemoradiotherapy for small cell lung cancer

The NRG-LU005 trial found that immunotherapy atezolizumab did not improve survival for patients with limited-stage small cell lung cancer when added to chemoradiation. Twice-daily radiation therapy, however, was associated with improved survival in this population.

SourceAlliance for Clinical Trials in Oncology·JournalJournal of Clinical Oncology·TypeRandomized controlled/clinical trial·DateMar 12, 2026
Anker Laptop Power Bank 25,000mAh (Triple 100W USB-C)

Anker Laptop Power Bank 25,000mAh (Triple 100W USB-C) keeps Macs, tablets, and meters powered during extended observing runs and remote surveys.